Capital Asset Advisory Services LLC Purchases New Holdings in Hims & Hers Health, Inc. $HIMS

Capital Asset Advisory Services LLC acquired a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 28,151 shares of the company’s stock, valued at approximately $998,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Hims & Hers Health by 23.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock valued at $12,373,000 after purchasing an additional 78,543 shares in the last quarter. Geneos Wealth Management Inc. purchased a new stake in shares of Hims & Hers Health in the 1st quarter worth approximately $30,000. Cetera Investment Advisers increased its position in Hims & Hers Health by 94.9% during the 2nd quarter. Cetera Investment Advisers now owns 58,888 shares of the company’s stock valued at $2,936,000 after buying an additional 28,672 shares in the last quarter. Rockefeller Capital Management L.P. raised its stake in Hims & Hers Health by 14.8% during the second quarter. Rockefeller Capital Management L.P. now owns 31,733 shares of the company’s stock valued at $1,582,000 after buying an additional 4,080 shares during the last quarter. Finally, Handelsbanken Fonder AB boosted its holdings in Hims & Hers Health by 10.2% in the second quarter. Handelsbanken Fonder AB now owns 45,300 shares of the company’s stock worth $2,258,000 after acquiring an additional 4,200 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on HIMS shares. Deutsche Bank Aktiengesellschaft increased their target price on Hims & Hers Health from $25.00 to $28.00 and gave the stock a “hold” rating in a research note on Tuesday, March 10th. Morgan Stanley dropped their price target on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 24th. Needham & Company LLC raised shares of Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 price objective on the stock in a research report on Monday, March 9th. Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday, December 29th. Finally, Barclays lifted their target price on shares of Hims & Hers Health from $25.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, March 11th. Three analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $31.29.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $21.39 on Wednesday. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $70.43. The firm has a market capitalization of $4.88 billion, a price-to-earnings ratio of 41.95, a price-to-earnings-growth ratio of 2.60 and a beta of 2.55. The company has a current ratio of 1.90, a quick ratio of 1.70 and a debt-to-equity ratio of 1.80. The firm has a 50 day moving average of $22.39 and a 200 day moving average of $36.29.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The business had revenue of $617.82 million for the quarter, compared to the consensus estimate of $619.48 million. During the same period last year, the firm earned $0.11 earnings per share. The company’s quarterly revenue was up 28.4% on a year-over-year basis. On average, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Buying and Selling

In other Hims & Hers Health news, COO Michael Chi sold 97,289 shares of the business’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $2,402,065.41. Following the completion of the sale, the chief operating officer owned 407,282 shares of the company’s stock, valued at approximately $10,055,792.58. The trade was a 19.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Soleil Boughton sold 4,812 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total value of $118,808.28. Following the completion of the sale, the insider owned 308,831 shares of the company’s stock, valued at approximately $7,625,037.39. The trade was a 1.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 125,767 shares of company stock valued at $3,238,953 in the last 90 days. 17.71% of the stock is owned by company insiders.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.